IgA肾病中皮质类固醇反应与结局的性别差异
本研究基于TESTING试验,纳入305例男性和198例女性IgA肾病患者,随机接受6-9个月口服甲泼尼龙或安慰剂,随访4.2年。主要结局为eGFR下降40%、肾衰竭或肾脏死亡。甲泼尼龙降低主要结局风险在男女中无显著交互作用,但男性主要结局风险高于女性,且eGFR下降更快。
要点
- 甲泼尼龙降低IgA肾病主要肾脏结局风险,男女疗效无显著差异。
- 男性IgA肾病患者主要肾脏结局风险显著高于女性。
- 男性eGFR下降速率比女性快3.13 ml/min/1.73m2/年。
核心结论
- 甲泼尼龙改善IgA肾病肾脏结局,不受性别影响,但男性肾脏结局较女性更差。
研究设计与样本
- TESTING试验的事后分析,纳入305例男性(61%)和198例女性(39%),随机接受6-9个月口服甲泼尼龙或安慰剂,平均随访4.2年。
主要发现
- 甲泼尼龙 vs 安慰剂的主要结局风险:男性HR 0.51(95%CI 0.35-0.74),女性HR 0.64(95%CI 0.38-1.09),交互P=0.47。
- 12个月蛋白尿较基线的降低和eGFR下降速率的减缓均无性别差异(交互P分别为0.28和0.81)。
- 男性主要结局风险高于女性(HR 1.44,95%CI 1.05-1.97,P=0.03)。
- 男性2年内eGFR下降速率比女性快3.13 ml/min/1.73m2/年(95%CI 0.92-5.34,P=0.006)。
临床怎么用
- 甲泼尼龙可用于IgA肾病患者,无需根据性别调整治疗决策。
- 男性IgA肾病患者可能需要更密切监测肾功能进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The impact of sex on treatment response and outcomes in IgA nephropathy (IgAN) remains uncertain. This analysis of the Therapeutic Effects of Steroids in IgAN Global (TESTING) trial aimed to evaluate the following: (i) the effect of sex on corticosteroid response and (ii) the association between sex and kidney outcomes in IgAN. METHODS: Participants with IgAN were randomized to 6 to 9 months of oral methylprednisolone or placebo. The primary outcome was a composite of 40% decline in estimated glomerular filtration rate (eGFR), kidney failure, or death because of kidney disease. The interaction between sex and treatment on the risk of the primary outcome, relative change in proteinuria, and total eGFR slope was tested. Cox models were used to estimate the risk of the primary outcome in males versus females. Sex differences in total eGFR slope were also estimated. RESULTS: Overall, there were 305 males (61%) and 198 females (39%). The mean follow-up period was 4.2 years. Compared with placebo, methylprednisolone lowered the risk of the primary outcome in both males (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.35-0.74) and females (HR: 0.64, 95% CI: 0.38-1.09) (P-interaction = 0.47), and reduced proteinuria from baseline at 12 months and slowed the rate of total eGFR decline, with no sex differences (P-interaction = 0.28 and 0.81, respectively). Males had a greater risk of the primary outcome than females (HR: 1.44, 95% CI: 1.05-1.97, P = 0.03). Total eGFR rate of decline over 2 years was greater in males compared with females by 3.13 ml/min per 1.73 m2/yr (95% CI: 0.92-5.34, P = 0.006). CONCLUSION: Methylprednisolone improves kidney outcomes in IgAN, regardless of sex; however, males experience poorer kidney outcomes than females.
引用
- Kim D, Woodward M, Lv J, et al. Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy. Kidney Int Rep. 2025. PMID: 41141501. doi:10.1016/j.ekir.2025.07.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。